Loading...
Market
Major safety concerns reported about BPaLM regimen by end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Union Health Ministry of India's official reports and medical journals
Story
India Approves BPaLM Regimen for Drug-Resistant TB
Sep 6, 2024, 11:51 AM
The Union Health Ministry of India has approved the introduction of a new, shorter, and more efficacious treatment regimen for drug-resistant tuberculosis (TB). The BPaLM regimen, which consists of a four-drug combination—Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin—has been proven to be safe and more effective. This novel treatment will be implemented under the National TB Elimination Program and is expected to benefit India's 75,000 drug-resistant TB patients.
View original story
Similar markets
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
No major side effects • 25%
No reports • 25%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
Revised guidelines • 25%
Increased studies • 25%
No change • 25%
Other actions • 25%
Confirms higher SAE rate in early batches • 25%
Confirms no difference in SAE rates • 25%
Finds other contributing factors • 25%
Inconclusive results • 25%
Yes • 50%
No • 50%
Nausea • 25%
Fatigue • 25%
Diarrhea • 25%
Other • 25%
None • 25%
Mild • 25%
Moderate • 25%
Severe • 25%
Yes • 50%
No • 50%
